5-APDB also known as 5-(2-Aminopropyl)-2,3-dihydrobenzofuran is an entactogen of the phenethylamine class and an analog of MDA differing by the substitution of a methylene bridge in place of the heterocyclic 3-position oxygen from the 3,4-methylenedioxy ring.
Introduction to 5-APDB
First synthesised in 1993 by David E. Nichols at Purdue University, 5-APDB was developed as part of a research study into non-neurotoxic MDMA analogs. 5-APDB acts as a moderately high selective serotonin releasing agent, as well as a triple monoamine reuptake inhibitor with IC50 values at 130 nM for serotonin, 7,089 nM for dopamine, and 3,238 nM for norepinephrine.
Using 5-APDB
Ways of Administration
5-APDB is most commonly administered through oral consumption, though many user also choose to insufflate the compound, however as is the case with many of the other selective serotonin releasing agents, oral consumption appears to be the most effective route of administration due to the vast amount of serotonin receptors which line the walls of the gastrointestinal tract.Effects of 5-APDB
Positive
- Euphoria
- Sedation
- Lethargy
- Feelings of empathy
- Mood enhancements
Neutral
- Mild visual distortions
- Mental cloudiness
Negative
- Hangover
- Lightheadedness
- Nausea
- Slurred speech
- Staggered movements
Chemistry of 5-APDB
Column 1 Column 2 Systematic (IUPAC) name: 1-(2,3-dihydro-1-benzofuran-5-yl)propan-2-amine Synonyms: EMA-4, 3-desoxy-MDA, 5-(2-Aminopropyl)-2,3-dihydrobenzofuran Molecular Formula: C11H15NO Molar mass: 177.24 g/mol [1] CAS Registry Number: 152623-94-4 Melting Point: Boiling Point: Flash Point: no data Solubility: Additionnal data: Notes:
The Dangers of 5-APDB
Being that 5-APDB is a relatively new compound to the research chemical market, there are still many unknown aspects involved with the compound. Likewise there have been no formal studies on the effects of 5-APDB in humans thus there is no established set of short term or long term side effects.
5-APDB is a psychoactive substance thus it should only be administered by users who are deemed mentally fit for the ingestion of such substances as users whom have a history or family history of mental illness have a higher chance for a psychotic episode to occur. Likewise users with known physical illnesses or a family history of physical illness should also avoid this compound as it may instigate such illnesses.
Legal Status of 5-APDB
United Nations
USA
While 5-APDB is not explicitly listed as a scheduled substance, it may still be considered an analog under the federal analog act.UK
As of June 10th 2013, 5-APDB and many other similar compounds have been classified as temporary class drugs following a recommendation by the ACMD.EU
Other Countries
5-APDB